WallStSmart

Tempus AI, Inc. Class A Common Stock (TEM)vs10X Genomics Inc (TXG)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Tempus AI, Inc. Class A Common Stock generates 98% more annual revenue ($1.27B vs $642.82M). TXG leads profitability with a -6.8% profit margin vs -19.3%. TXG earns a higher WallStSmart Score of 32/100 (F).

TEM

Avoid

31

out of 100

Grade: F

Growth: 8.0Profit: 2.0Value: 5.0Quality: 5.5
Piotroski: 6/9Altman Z: -2.16

TXG

Avoid

32

out of 100

Grade: F

Growth: 4.7Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 5/9

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

TEM1 strengths · Avg: 10.0/10
Revenue GrowthGrowth
83.0%10/10

Revenue surging 83.0% year-over-year

TXG0 strengths · Avg: 0/10

No standout strengths identified

Areas to Watch

TEM4 concerns · Avg: 3.0/10
Price/BookValuation
16.9x4/10

Trading at 16.9x book value

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-89.5%2/10

ROE of -89.5% — below average capital efficiency

Free Cash FlowQuality
$-51.78M2/10

Negative free cash flow — burning cash

TXG4 concerns · Avg: 2.8/10
Revenue GrowthGrowth
0.6%4/10

0.6% revenue growth

EPS GrowthGrowth
0.0%4/10

0.0% earnings growth

Return on EquityProfitability
-5.8%2/10

ROE of -5.8% — below average capital efficiency

Profit MarginProfitability
-6.8%1/10

Currently unprofitable

Comparative Analysis Report

WallStSmart Research

Bull Case : TEM

The strongest argument for TEM centers on Revenue Growth. Revenue growth of 83.0% demonstrates continued momentum.

Bull Case : TXG

TXG has a balanced fundamental profile.

Bear Case : TEM

The primary concerns for TEM are Price/Book, EPS Growth, Return on Equity. Debt-to-equity of 2.63 is elevated, increasing financial risk.

Bear Case : TXG

The primary concerns for TXG are Revenue Growth, EPS Growth, Return on Equity.

Key Dynamics to Monitor

TEM profiles as a hypergrowth stock while TXG is a turnaround play — different risk/reward profiles.

TEM is growing revenue faster at 83.0% — sustainability is the question.

TXG generates stronger free cash flow (39M), providing more financial flexibility.

Monitor HEALTH INFORMATION SERVICES industry trends, competitive dynamics, and regulatory changes.

Bottom Line

TXG scores higher overall (32/100 vs 31/100). Both earn "Avoid" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Tempus AI, Inc. Class A Common Stock

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

Tempus AI, Inc is a healthcare technology company. The company is headquartered in Chicago, Illinois.

Visit Website →

10X Genomics Inc

HEALTHCARE · HEALTH INFORMATION SERVICES · USA

10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and Asia Pacific. The company is headquartered in Pleasanton, California.

Want to dig deeper into these stocks?